Eli Lilly seeks to expand Zepbound use to treat sleep apnea - Yahoo Finance
- Eli Lilly seeks to expand Zepbound use to treat sleep apnea Yahoo Finance
- Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks Bloomberg
- Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and Company
- Amid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod FiercePharma